Stem cells aim to reverse frailty in the elderly

NCT ID NCT07144072

Not yet recruiting Disease control Sponsor: Hexun Biosciences Co., LTD. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests a new stem cell treatment called HeXell-2020 in 12 elderly people with mild to moderate frailty. The treatment uses donated umbilical cord stem cells given through an IV. The main goal is to check safety and find the best dose, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HeXell-2020 (umbilical cord stem cells)
What this could lead to: If safe and effective, this could point toward a treatment to improve physical function and reduce frailty in older adults.
What could go wrong: This is a very early, small Phase 1 trial with only 12 people, focused on safety. It is not designed to prove the treatment works, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAILTY IN OLDER ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAILTY IN OLDER ADULTS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.